Close Menu

NEW YORK – NeoGenomics today reported a 50 percent year-over-year uptick in its second quarter revenues with strong growth in both its clinical services and pharma services businesses.

For the three months ended June 30, total revenues reached $101.7 million, up from $67.7 million in Q2 2018, and beating analysts' average estimate of $97.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.